Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. - Wikidata - awgldk - TriplyDB

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

http://www.wikidata.org/entity/Q50553843

about

Evaluation of brain iron content based on magnetic resonance imaging (MRI): comparison among phase value, R2* and magnitude signal intensity Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker.Role of iron in neurodegenerative diseases.In vivo evaluation of microglia activation by intracranial iron overload in central pain after spinal cord injury Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.Brain iron redistribution in mesial temporal lobe epilepsy: a susceptibility-weighted magnetic resonance imaging study.Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo Wilson's disease and other neurological copper disorders.Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease Copper chelation and interleukin-6 proinflammatory cytokine effects on expression of different proteins involved in iron metabolism in HepG2 cell line.Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases.Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements.Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction.Copper and copper proteins in Parkinson's disease.Effect of oxidative stress induced by intracranial iron overload on central pain after spinal cord injury.Antioxidant gene therapy against neuronal cell death.Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.Magnetic Resonance Imaging (MRI) in Parkinson's Disease.Is early-life iron exposure critical in neurodegeneration?Alpha-synuclein: relating metals to structure, function and inhibition.Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Overview of iron metabolism in health and disease.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.Oxidative modification of human ceruloplasmin induced by a catechol neurotoxin, salsolinol Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance.Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.Occupational Metal Exposure and Parkinsonism.Deep-gray nuclei susceptibility-weighted imaging filtered phase shift in patients with Wilson's disease.Role of Iron and Copper in the Pathogenesis of Parkinson's Disease.Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.Parkinson's disease: diagnostic potential of high-resolution phase difference enhanced MR imaging at 3 T.Ceruloplasmin is Involved in the Nigral Iron Accumulation of 6-OHDA-Lesioned Rats.

P2860

Q28731919-D50C516C-7226-4450-B835-56F099C3026F Q30837513-8C2BED3C-673C-4DC8-BE3B-50345F12A45A Q31038817-C6013686-A336-4694-9F2C-BCCA05C8E137 Q33706685-7478B019-3B08-40CB-8506-547CA90701EA Q33965221-58AAA8E8-0774-4A31-9A68-834822923644 Q34372099-78950836-CA56-44B5-BC24-DEDCBCC3B468 Q34489342-EE8F208C-179B-4C82-8C97-FC1073363A27 Q34568633-4EAAFA31-A925-4EC5-9295-7377A374CB37 Q34639246-957C75BC-47FD-4753-B8DE-A6E6C68D3FB5 Q35106874-CC8D67BC-FA0C-4216-9FE8-DEF1ACA95058 Q35626417-4A17F53A-0AAD-440C-81BB-91478D150BCB Q36259104-C14F56B4-7904-4625-A17E-CCF40CF58C28 Q36374541-687EF052-04FD-4A0F-B7A9-AAB0AC71ABE2 Q37068758-0C7A8A7B-ECC6-4D3B-8F4A-7B9076912152 Q37402514-6F4B8DC8-B721-42B1-A087-880DAD404010 Q37587232-96608A4C-3461-4BF9-B7AB-41659F649F82 Q37616391-EF625B2F-2756-4D9A-9834-588FCCCEDE38 Q37633719-EEC1573F-FEAA-4CCB-8585-321BE771373B Q37647941-090D0D6D-F10C-4A01-AB06-3CA0CEE956A0 Q37947588-F9190B57-BE1C-4BB1-B2E5-F493C6512D59 Q38281082-3960BD5A-E11B-419D-B60D-4470DE21691B Q38534920-2AD67197-6AB4-414E-906D-8CF43D42AD3A Q38728563-7290156F-8E46-41A2-9FB5-9FFE3060C7EB Q38901449-CAEF0B48-BE98-4AD1-A7BC-FBED9B2A86FD Q39179797-B1321F4C-4605-4BC5-876D-134337B6EF15 Q39179833-5734E08D-3F56-4F39-9026-74C67BD85359 Q39199926-F90BF444-B7A4-4958-9419-7A668C40BA17 Q40017984-27E10332-6BF0-4B46-B220-F22CB1C7FABC Q41339641-18CE6613-7294-477D-87F3-8DCC7EBDB870 Q41825693-02B120DA-4BF1-4D4C-8FAC-C25E092F36BA Q42197717-EB5DC3EE-F66D-4671-8457-9B848D0D1B8E Q45736610-6D46333F-7D80-4A89-8ADE-136902614DCA Q46009075-4EE3425A-74CF-48EB-A97D-BB14B9A1891A Q46309593-DF902ECD-F678-4D60-9774-18A9F412FCCC Q46930460-47E43689-8AE3-4E3A-9792-43AF1D583B60 Q47947787-97B956F0-4200-40DE-A52B-B69F0416FEDC Q48129184-FC83065B-006B-4D39-9AEC-7574E110CBB7 Q48282777-5CFB42E9-D61D-44B9-B7FC-A57D5F8CDB65 Q48329843-27DA20F7-AECA-40E8-A04C-3B78416F13A9 Q48341689-15610D26-A5E1-4326-870C-38D7F4ED37CC

P2860

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

http://www.wikidata.org/entity/Q50553843

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@en

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@nl

type

label

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@en

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@nl

prefLabel

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@en

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@nl

P1433

Q50553843-C0A7D51F-338C-4A16-826C-7018B0B94AF9

P1476

Q50553843-E0A33B81-B73A-44AB-B4DC-5A27371842AD

P2093

Q50553843-09613156-1BBE-4B5F-94F8-3AF14F4C2A7E

Q50553843-2D918970-7A9C-4DAA-A2B9-CECD2F36A551

Q50553843-5D81392C-1A0E-4C24-B5BE-B733773C8DF8

Q50553843-8C727C83-21A4-460A-AF78-7CCAAF5E9F9D

Q50553843-AEB023A0-EDEA-4C0B-A36B-02D7C5F95D3B

Q50553843-F011A6E3-FEAE-494B-9349-652B235C8AD3

Q50553843-F9AAD2FA-1871-4D55-A3F8-2A2C28370C9D

Q50553843-FAB117B6-DE6C-478C-8CE6-C4F6D6CC6EE1

P2860

Q50553843-056DFCCD-5733-4C36-ABE2-60E9B91E5C56

Q50553843-08437A99-F23F-4C49-8BCE-A6B739C9DDBB

Q50553843-1D46943F-BE33-453A-BE5D-7D0A25DEBE67

Q50553843-2323F696-3348-4B1C-BFB2-1943CC7AC95E

Q50553843-26785E6E-F57A-4DD8-A1DA-C8C914C7220C

Q50553843-29057D45-7463-44C6-8C01-330525A6BE23

Q50553843-2A5EF0CA-30F8-4BCC-965A-38890CB00AD6

Q50553843-2E31A299-1D83-4FA9-81D0-25BE98FCCEF8

Q50553843-38E4E1EE-975F-4CD6-9AF2-6C65F10798F1

Q50553843-4B7D2C41-03F2-4E1B-AEAE-868C072086F1

P304

Q50553843-680C3756-0E56-4B63-BAE6-B3983A616FFB

P31

Q50553843-BBC12A5B-08D2-45CB-829B-9E814103AE9C

P356

Q50553843-EA216DB7-D8AC-4377-8F8A-062CB9E2F984

P407

Q50553843-BC199F6C-1B72-46AC-925E-ECED0B646D7B

P433

Q50553843-CA7B97EF-35B2-4B45-84E4-E0ADABE0E772

P478

Q50553843-83238445-49C8-43BB-BDEB-9532BB26D7F9

P577

Q50553843-AC1D5AB7-C818-4A5A-A9AE-21CBC2D8C0DA

P698

Q50553843-C87545B0-B816-4FC6-A488-28E363010BFC

P921

Q50553843-76F3B2DF-02EB-433C-A90C-96454F973EEC

P356

P1433

P1476

Decreased serum ceruloplasmin ...... sition in Parkinson's disease.

@en

P2093

Chunjiu Zhong

http://www.w3.org/2001/XMLSchema#string

Guoqiang Fei

http://www.w3.org/2001/XMLSchema#string

Hang Jin

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Lei Zhao

http://www.w3.org/2001/XMLSchema#string

Lirong Jin

http://www.w3.org/2001/XMLSchema#string

Mengsu Zeng

http://www.w3.org/2001/XMLSchema#string

Yuwen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Aceruloplasminemia: molecular characterization of this disorder of iron metabolism

Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging

Staging of brain pathology related to sporadic Parkinson's disease

Iron, brain ageing and neurodegenerative disorders

Oxidative stress in Parkinson's disease

Susceptibility weighted imaging (SWI).

Imaging iron stores in the brain using magnetic resonance imaging.

Iron metabolism in Parkinsonian syndromes.

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

Potential role of high-field MRI for studies in Parkinson's disease.

P304

50-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWQ319

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21109502

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease